Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
Crossref DOI link: https://doi.org/10.1007/s40261-016-0376-0
Published Online: 2016-02-19
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Vilsbøll, Tina
Vora, Jiten
Jarlov, Henrik
Kvist, Kajsa
Blonde, Lawrence
Funding for this research was provided by:
Novo Nordisk (DK)
License valid from 2016-02-19